Microglial activation mediates neurodegeneration related to oligodendroglial α-synucleinopathy: Implications for multiple system atrophy

Movement Disorders

Volumn 22, Issue 15, 2007, Pages 2196-2203

  Stefanova, Nadia ^a   Reindl, Markus ^a   Neumann, Manuela ^b   Kahle, Philipp J ^c   Poewe, Werner ^a   Wenning, Gregor K ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Microglial activation; Multiple system atrophy; Neurodegeneration; Transgenic mouse; synuclein

Indexed keywords

ALPHA SYNUCLEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MINOCYCLINE; PLACEBO; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; HISTOPATHOLOGY; HUMAN; IMMUNOREACTIVITY; IN VIVO STUDY; MICROGLIA; MORPHOMETRICS; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHY DRAGER SYNDROME; SUBSTANTIA NIGRA; TRANSGENIC MOUSE;

EID: 36949032824     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21671     Document Type: Article

References (31)

1. Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004;3:93-103.
2. Ishizawa K, Komori T, Sasaki S, Arai N, Mizutani T, Hirose T. Microglial activation parallels system degeneration in multiple system atrophy. J Neuropathol Exp Neurol 2004;63:43-52.
3. Gonzalez-Scarano F, Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 1999;22:219-240.
4. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004;10 Suppl 1:S3-S7.
5. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005;57:168-175.
6. Orr CF, Rowe DB, Halliday GM. An inflammatory review of Parkinson's disease. Prog Neurobiol 2002;68:325-340.
7. Lehnardt S, Massillon L, Follett P, et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci USA 2003;100:8514-8519.
8. Palsson-McDermott EM, O'Neill LA. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4 Immunology 2004;113:153-162.
9. Liu Y, Walter S, Stagi M, et al. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain 2005;128:1778-1789.
10. Gerhard A, Banati RB, Goerres GB, et al. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 2003;61:686-689.
11. Kahle PJ, Neumann M, Ozmen L, et al. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 2002;3:583-588.
12. Yazawa I, Giasson BI, Sasaki R, et al. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 2005;45:847-859.
13. Shults CW, Rockenstein E, Crews L, et al. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci 2005;25:10689-10699.
14. Stefanova N, Reindl M, Neumann M, et al. Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 2005;166:869-876.
15. Kahle PJ, Neumann M, Ozmen L, et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci 2000;20:6365-6373.
16. Mishra BB, Mishra PK, Teale JM. Expression and distribution of Toll-like receptors in the brain during murine neurocysticercosis. J Neuroimmunol 2006;181:46-56.
17. Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002;61:1013-1021.
18. Xia Y, Yamagata K, Krukoff TL. Differential expression of the CD14/TLR4 complex and inflammatory signaling molecules following i.c.v. administration of LPS. Brain Res 2006;1095:85-95.
19. Mayhew TM, Gundersen HJ. If you assume, you can make an ass out of u and me': a decade of the disector for stereological counting of particles in 3D space. J Anat 1996;188(Part 1):1-15.
20. Joyce JN, Presgraves S, Renish L, et al. Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP): a comparison to ropinirole. Exp Neurol 2003;184:393-407.
21. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000;6:797-801.
22. Diguet E, Fernagut PO, Wei X, et al. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci 2004;19:3266-3276.
23. Wang X, Zhu S, Drozda M, et al. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 2003;100:10483-10487.
24. Smith DL, Woodman B, Mahal A, et al. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 2003;54:186-196.
25. Stefanova N, Mitschnigg M, Ghorayeb I, et al. Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. J Neurosci Res 2004;78:87-91.
26. Hunter CL, Bachman D, Granholm AC. Minocycline prevents cholinergic loss in a mouse model of Down's syndrome. Ann Neurol 2004;56:675-688.
27. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-78.
28. Seabrook TJ, Jiang L, Maier M, Lemere CA. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice Glia 2006;53:776-782.
29. Quintero EM, Willis L, Singleton R, et al. Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease. Brain Res 2006;1093:198-207.
30. Hoshino K, Takeuchi O, Kawai T, et al. Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999;162:3749-3752.
31. Stefanova N, Tison F, Reindl M, Poewe W, Wenning GK. Animal models of multiple system atrophy. Trends Neurosci 2005;28:501-506.